Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fanconi anemia (FA) is a congenital disease characterized by bone marrow failure and increased incidence of malignant tumors. The Project pursue the optimization of the collection of hematopoietic progenitor cells for later use in another clinical trial entitled "Clinical Trial Phase I/II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells mobilized with mozobil and filgrastim, and transduced with a lentiviral vector carrying the FANCA gene (Orphan Drug) for patients with Fanconi Anemia Subtype A ". The objectives of this study are, therefore, to assess the safety and efficacy of CD34+ cells mobilization with mozobil and filgrastim, which is postulated the most efficient for the collection of CD34+ cells from FA patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

NCT03157804

Fanconi Anemia

COMPLETED PHASE1/PHASE2

Gene Therapy for Fanconi Anemia

NCT01331018

Fanconi Anemia

TERMINATED PHASE1

Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

NCT04069533

Fanconi Anemia Complementation Group A

ACTIVE_NOT_RECRUITING PHASE2

Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia

NCT00005896

Fanconi's Anemia

UNKNOWN PHASE1

Hematopoietic Stem Cell Transplant for Fanconi Anemia

NCT01071239

Fanconi Anemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fanconi Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

plerixafor and filgrastim treatment

to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim

Group Type EXPERIMENTAL

filgrastim

Intervention Type DRUG

G-CSF (12 μg/Kg/12 h) 8 days.

plerixafor

Intervention Type DRUG

Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

filgrastim

G-CSF (12 μg/Kg/12 h) 8 days.

Intervention Type DRUG

plerixafor

Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female \> 1 year
* diagnosed of Fanconi's anemia confirmed by instability chromosomal test with diepoxy-butane or mitomycin C
* At least one of the following parameters must be higher than these values: Hemoglobin:8,0 g/dL; neutrophils: 750/mm3; platelets: 30.000/mm3
* Lansky index\> 60%.
* Left ventricular ejection fraction \>50%.
* To grant informed consent in agreement with current law norms
* Women in childbearing age must obtain a negative result in the pregnancy test in serum or urine in the visit of selection and accept the use of suitable contraceptive methods since at least 14 days prior to the first dose of mobilizing treatment until the 14 days following the last

Exclusion Criteria

* Evidence of myelodysplastic syndromes or leukemia, or cytogenetic abnormalities predicted of these syndromes in bone marrow aspiration. Cytogenetic analyses performed 2 months before starting study are accepted
* Patients with active infection process or any other underlaying severe medical process
* Severe Functional alteration of organs (hepatic, renal, respiratory)(?3), according to National Cancer Institute (NCI CTCAE v3) criteria
* Haematopoietic transplant
* Any disease or concomitant process that is not compatible with the study as per investigator opinion
* Patients not elegible because of an psico-social evaluation
* Patients that received transfusional support during the last 3 months.
* Pregnant or breastfeeding women

Minimum Eligible Age

2 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No